|Day Low/High||3.46 / 3.72|
|52 Wk Low/High||2.81 / 7.72|
Let's get out the magnifying glass and examine GNPX's selling of 4 million shares and the hit it took on Tuesday.
After GNPX's private placement on Tuesday, I spoke with the CEO, Rodney Varner. Here's what I found out and what my views are on the developer of cancer and diabetes therapies.
The options don't give a ton of choices, but I like the buy-write.
As the pundits decide who won, I'm looking at these biotech names with a focus on Myovant Sciences.
2021 will be a big year, upside is at least twice the current valuation, and downside is limited to 10% from current levels.
After reviewing the rally, let's zero in on one biotech name, Genprex, and where it appears to be going.
Firms should be using their high stock price to grab other businesses to expand, so they're ready when things return to normal.
Two names I've talked about, AYRO and GNPX, saw their stories get closer to reality on Tuesday.
The initial target here is $16 with a secondary target of $17.50 on this breakout, with a time frame of a month or less.
A desperate deal by Genprex could spell opportunity for investors. Here's how.
The small biotech's market cap sits at $125 million, the low end of what I believe is fair.
I've followed this name before it went public, and it's got some potentially promising treatments in its pipeline.
If you want a perfect example of this, look at two recent capital raises: one from Tesla and one from Genprex over the past week.
For those who love a roll of the dice, GNPX may be worth a closer look.
Strong balance sheet and royalties are big positives for Innoviva.